Author ’s Reply to Kow et al.: “Comparison of Clinical Outcomes between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”
(Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - January 25, 2024 Category: Cardiology Source Type: research
The FGG c.952G > A variant causes congenital dysfibrinogenemia characterized by recurrent cerebral infarction: a case report
ConclusionThis case report expands the clinical phenotype spectrum associated with FGG c.952G>A (rs267606810) and underscores the significance of considering CD as a potential etiology for unexplained ischemic stroke, particularly in patients with a family history of coagulation disorders. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - January 24, 2024 Category: Neurology Source Type: research
The Complement System and C4b-Binding Protein: A Focus on the Promise of C4BPα as a Biomarker to Predict Clopidogrel Resistance
AbstractThe complement system plays a dual role in the body, either as a first-line defense barrier when balanced between activation and inhibition or as a potential driver of complement-associated injury or diseases when unbalanced or over-activated. C4b-binding protein (C4BP) was the first circulating complement regulatory protein identified and it functions as an important complement inhibitor. C4BP can suppress the over-activation of complement components and prevent the complement system from attacking the host cells through the binding of complement cleavage products C4b and C3b, working in concert as a cofactor fo...
Source: Molecular Diagnosis and Therapy - January 23, 2024 Category: Molecular Biology Source Type: research
Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program
CONCLUSION: A multidisciplinary collaboration is recommended to facilitate the use of CYP2C19 genotype-guided antiplatelet therapy in patients with cardiovascular and cerebrovascular diseases. Evolving clopidogrel pharmacogenetic evidence necessitates thoughtful iteration of implementation efforts and strategies to optimize long-term maintenance and sustainability.PMID:38253063 | DOI:10.1093/ajhp/zxae008 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - January 22, 2024 Category: Drugs & Pharmacology Authors: Christina L Aquilante Katy E Trinkley Yee Ming Lee Kristy R Crooks Emily C Hearst Simeon M Heckman Kaitlyn W Hess Elizabeth L Kudron James L Martin Carolyn T Swartz David P Kao Source Type: research
Impact of Platelet Reactivity on One-year Clinical Outcomes after Endovascular Therapy for Femoropopliteal Lesions
Dual antiplatelet therapy with aspirin plus P2Y12 inhibitor for at least 1 month after endovascular therapy (EVT) is recommended in symptomatic lower extremity arterial disease (LEAD) with femoropopliteal (FP) lesions [1]. However, the pharmacodynamic response to antiplatelet medication differs between individuals. In particular, greater individual differences in platelet reactivity to clopidogrel, one of the P2Y12 inhibitors, have been reported compared to aspirin [2]. Several previous studies evaluated the association of platelet reactivity with clinical outcomes in the area of LEAD management, but their conclusions were...
Source: The American Journal of Cardiology - January 22, 2024 Category: Cardiology Authors: Takuya Tsujimura, Osamu Iida, Mitsuyoshi Takahara, Kazuki Tobita, Daizo Kawasaki, Masahiko Fujihara, Sinya Sasaki, Hiroyoshi Yokoi, Kenji Suzuki, Toshiaki Mano Tags: Brief report Source Type: research
Impact of Platelet Reactivity on 1-Year Clinical Outcomes After Endovascular Therapy for Femoropopliteal Lesions
Dual antiplatelet therapy with aspirin plus P2Y12 inhibitor for at least 1 month after endovascular therapy (EVT) is recommended in symptomatic lower extremity arterial disease (LEAD) with femoropopliteal (FP) lesions.1 However, the pharmacodynamic response to antiplatelet medication differs between individuals. In particular, greater individual differences in platelet r eactivity to clopidogrel, one of the P2Y12 inhibitors, have been reported compared with aspirin.2 Several previous studies evaluated the association of platelet reactivity with clinical outcomes in the area of LEAD management, but their conclusions were ...
Source: The American Journal of Cardiology - January 22, 2024 Category: Cardiology Authors: Takuya Tsujimura, Osamu Iida, Mitsuyoshi Takahara, Kazuki Tobita, Daizo Kawasaki, Masahiko Fujihara, Sinya Sasaki, Hiroyoshi Yokoi, Kenji Suzuki, Toshiaki Mano Tags: Brief Report Source Type: research
Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation
ConclusionLowering the maintenance dose of ticagrelor from 90 to 60 mg bid effectively reduces bleeding risk without increasing thrombotic infarction risk in elderly, small-weight Asian females. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - January 20, 2024 Category: Drugs & Pharmacology Source Type: research
Increased Risk of Adverse Outcomes in Black Patients Undergoing Carotid Artery Stenting is Associated with Underutilization of Perioperative Antiplatelet Therapy
This study aims to characterize antiplatelet use in Black patients undergoing CAS and examine if the pattern contributes to adverse outcomes in these patients. (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - January 18, 2024 Category: Surgery Authors: Nishita R. Vootukuru Source Type: research
Effect of ticagrelor versus clopidogrel after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome —propensity score matching analysis
The effect of different dual antiplatelet therapies on thrombotic events on the background of intravascular ultrasound (IVUS) guidance is unclear. We investigated whether ticagrelor can provide any additional ... (Source: BMC Cardiovascular Disorders)
Source: BMC Cardiovascular Disorders - January 18, 2024 Category: Cardiology Authors: Yinan Zhao, Yuxin Yang, Lei Guo, Dapeng Shen, Zhichao Dong, Yajuan Lin, Hao Liu, Yushan Wei and Bo Zhang Tags: Research Source Type: research
Frailty and P2Y12 Inhibitors: Does The Best Approach Need to Be Black or White?
We have read with interest the manuscript by Ko et al1 about frailty and P2Y12 inhibitors. As the authors state, the choice of the most adequate antiplatelet therapy is key, and it is 1 of the most challenging issues in the care of this subgroup of patients. In their series, the 2 major players limiting the use of prasugrel and ticagrelor were anemia and frailty, but despite these factors, the use of clopidogrel was reduced from 78.3% in the period 2010 to 2013 to 42.1% in the interval 2018 to 2020. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 17, 2024 Category: Cardiology Authors: I ñigo Lozano, Jose M. Vegas, Juan Rondan Tags: Readers ’ Comments Source Type: research
The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing
ConclusionNASM-PCR as a rapid genetic test holds promise for personalizing antiplatelet therapy in Asian CCS patients. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 15, 2024 Category: Cardiology Source Type: research
Delayed leukoencephalopathy following non-coil embolization flow diverter stent deployment for an intracranial aneurysm
This report examines delayed leukoencephalopathy as a postoperative complication after the use of flow diverter (FD) devices for endovascular cerebral aneurysm treatment. A case involving a 78-year-old female treated with a pipeline embolization device for a left internal carotid artery aneurysm is presented. Despite adherence to dual anti-platelet therapy, the patient developed intermittent headaches and memory issues 3 months post-operation. MRI revealed T1-enhancing foci and T2 hyperintense signal abnormalities in the left cerebral hemisphere, without new ischemic lesions, indicating potential embolic events or foreig...
Source: Neuroradiology - January 12, 2024 Category: Radiology Source Type: research
Short- versus long-term Dual AntiPlatelet Therapy for Stent-Assisted treatment of CErebral aneurysm (DAPTS ACE): a multicenter, open-label, randomized clinical trial
Conclusions
In this multicenter randomized controlled trial, there was not a statistically significant difference in the rate of ischemic strokes between long- and short-term DAPT. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - January 12, 2024 Category: Neurosurgery Authors: Ozaki, T., Yamagami, H., Morimoto, M., Hatano, T., Oishi, H., Haraguchi, K., Yoshimura, S., Sugiu, K., Iihara, K., Matsumaru, Y., Matsumoto, Y., Satow, T., Hayakawa, M., Sakai, C., Miyamoto, S., Kitagawa, K., Daimon, T., Kagimura, T., Sakai, N. Tags: Open access, Hemorrhagic stroke Source Type: research
